Interim Results From The Promise Study Of Opn-2853 With Ruxolitinib In Myelofibrosis

2025 1:21
Synopsis
Adam Mead, MA, BM, BCh, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the ...

You Might Also Like

Adam Mead, MD, on PROMise trial updates in myelofibrosis 4:35
Adam Mead, Md, On Promise Trial Updates In Myelofibrosis
2025
PROMise trial update: OPN-2853 plus rux in advanced MF with inadequate response to rux alone 1:35
Promise Trial Update: Opn-2853 Plus Rux In Advanced Mf With ...
2025
Interim Data Gives Hope to Myelofibrosis Patients Facing Sup-Optimal Results from Ruxolitinib Alone 4:34
Interim Data Gives Hope To Myelofibrosis Patients Facing Sup...
2021
Interim analysis of add-on parsaclisib in myelofibrosis with suboptimal ruxolitinib response 2:33
Interim Analysis Of Add-on Parsaclisib In Myelofibrosis With...
2021
Phase II study of pre-, during-, and post-transplant ruxolitinib for patients with myelofibrosis 2:36
Phase Ii Study Of Pre-, During-, And Post-transplant Ruxolit...
2021
The promise of momelotinib in the treatment of myelofibrosis 3:00
The Promise Of Momelotinib In The Treatment Of Myelofibrosis
2022
Updated results from MANIFEST arm 2: pelabresib as add-on to ruxolitinib in myelofibrosis 3:43
Updated Results From Manifest Arm 2: Pelabresib As Add-on To...
2023
Dr. Harrison on 5-Year Follow-Up Data on Ruxolitinib in Patients With Myelofibrosis 2:30
Dr. Harrison On 5-year Follow-up Data On Ruxolitinib In Pati...
2015
Results for the follow-up of the RESPONSE study 1:46
Results For The Follow-up Of The Response Study
2015
The impact of early intervention in myelofibrosis 2:36
The Impact Of Early Intervention In Myelofibrosis
2022
ACE-536-MF-001 update: luspatercept for the treatment of anemia in myelofibrosis 2:26
Ace-536-mf-001 Update: Luspatercept For The Treatment Of Ane...
2023
Download Options
Choose a download method below. All links open in new tabs.
Service Features Action
SaveFrom
MP4 & MP3 • HD Quality • Browser Extension Available
Download
Security Notice: These are third-party services. We recommend using antivirus software and being cautious of pop-up ads.